Pascal Soriot

Type: Person
Name: Pascal Soriot
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

The Best Reason To Buy AstraZeneca plc

The FTSE's second-biggest pharmaceuticals company AstraZeneca (LSE:AZN) (NYSE: AZN) has been in the news over the past year, with its share price having been boosted by the Pfizer bid attempt, to 4,573p today.But are AstraZeneca shares worth buying? I ... [Published Interactive Investor - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 1 reports

Heart disease to cost UK £18.4bn by 2020

In less than six years heart disease will cost the UK €23.1bn (£18.4bn), according to the Centre for Economic and Business Research.The UK will be one of the hardest hit countries in Western Europe by cardiovascular disease, the figures suggest, with ... [Published City A.M. - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 2 reports

Window opens for Pfizer move on AstraZeneca

Published:US drugs giant Pfizer can today renew its ambitions to buy AstraZeneca in a £69billion mega-deal.The Viagra-maker is looking for a way to slash its global tax bill by shifting its tax base out of the US. Its initial attempts to buy Astra, Britain’s ... [Published Mail Online UK - Aug 25 2014]
First reported Aug 20 2014 - Updated Aug 21 2014 - 1 reports

AstraZeneca Heart Drug Trial No Longer Subject of a Federal Probe

AstraZeneca says the Department of Justice is ending its investigation into PLATO, a clinical trial with its heart drug Brilinta, and is not planning any further action. It began investigating the PLATO trial, which studied more than 18,000 patients in ... [Published TheStreet.com - Aug 20 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

The Risks Of Investing In AstraZeneca plc

Today I am highlighting what you need to know before investing in AstraZeneca (LSE: AZN) (NYSE: AZN.US).Sales projections to haunt AstraZeneca later on?In a bid to stave off the overtures of US rival Pfizer, AstraZeneca chief executive Pascal Soriot announced ... [Published Yahoo! UK and Ireland - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

No investigation of Brilinta

The United States Department of Justice has announced that it closes its investigation into PLATO clinical trial for AstraZeneca’s Brilinta.In the PLATO study, Brilinta (ticagrelor) was compared to clopidrogel combined with acetylsalicylic acid. The studied ... [Published Nordic Life Science - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 3 reports

AstraZeneca Allowed to Market Heart Drug as Federal Probe Closed

AstraZeneca has won approval from the U.S. government to market its new heart drug Brilinta, following a federal probe. The company said the Department of Justice said it is closing its investigation into PLATO, a clinical trial with the drug, and is ... [Published TheStreet.com - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 5 reports

US Department of Justice closes investigation into AZ's PLATO clinical trial for Brilinta

19 Aug 14AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further ... [Published PharmiWeb - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

AstraZeneca plc’s Dividends Are Sliding

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been providing investors with attractive dividend yields for years -- those blockbuster drugs do cost a lot of money to being to market, but once they've gained approval, they can be cash cows for years to co ... [Published Yahoo! UK and Ireland - Aug 18 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

AstraZeneca to purchase Almirall's respiratory disease business

:05 in Pharmaceutical Company Restructures AstraZeneca has agreed a deal to purchase the respiratory franchise of fellow pharmaceutical company Almirall. The firm will pay an initial consideration of $875 million (520.14 million pounds) when the transaction ... [Published Zenopa - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Pascal Soriot | AstraZeneca

At the time Pascal Soriot took over AstraZeneca, the pharma giant was in trouble as a number of its major product patents had expired. The CEO has revitalised the company by investing in R&DWhen Pascal Soriot took over AstraZeneca, the company’s profits ... [Published European CEO - Aug 04 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 16 reports

AstraZeneca shows resilience

Ben Hirschler LondonASTRAZENECA raised its sales and earnings forecasts for the year yesterday, showing resilience after seeing off a $118 billion (R1 trillion) takeover approach from rival Pfizer two months ago.Second-quarter sales and earnings both ... [Published Daily News South Africa - Aug 01 2014]

More Content

All (212) | News (184) | Reports (0) | Blogs (20) | Audio/Video (0) | Fact Sheets (0) | Press Releases (6)
sort by: Date | Relevance
The Best Reason To Buy AstraZeneca plc [Published Interactive Investor - Aug 29 2014]
Round two? Market rumors on a new Pfizer bid fo... [Published FierceBiotech - Aug 29 2014]
US Department of Justice Closes Investigation i... [Published 4 Traders - Aug 28 2014]
Will Pfizer Take One Last Swing at AstraZeneca? [Published InvestorPlace.com - Aug 27 2014]
Heart disease to cost UK £18.4bn by 2020 [Published City A.M. - Aug 27 2014]
Western drugmakers try to shop their way out of... [Published Nikkei Asian Review - Aug 27 2014]
Window opens for Pfizer move on AstraZeneca [Da... [Published BusinessWeek - Aug 26 2014]
A New Pfizer Inc. Bid For AstraZeneca plc? [Published Yahoo! UK and Ireland - Aug 26 2014]
Window opens for Pfizer move on AstraZeneca [Published Mail Online UK - Aug 25 2014]
Round two: Window opens for Pfizer move on Astr... [Published This Is Money - Aug 25 2014]
Eli Lilly insulin receives tentative US approval [Published The Gulf Today - Aug 25 2014]
Balfour Beatty: The fine line between boldness ... [Published Telegraph - Aug 23 2014]
AstraZeneca shores up defences against Pfizer [Published Pharmafocus - Aug 22 2014]
Pfizer Back For AstraZeneca? Year-end Move Seen... [Published Clusterstock - Aug 21 2014]
Pfizer back for AstraZeneca? Year-end move seen... [Published London South East - Aug 21 2014]
AstraZeneca: DoJ Closes Investigation into PLAT... [Published Pharmacy Choice - Aug 21 2014]
The Risks Of Investing In AstraZeneca plc [Published Yahoo! UK and Ireland - Aug 21 2014]
AstraZeneca Is Tougher Pfizer Target as Possibl... [Published Washington Post - Aug 21 2014]
No investigation of Brilinta [Published Nordic Life Science - Aug 20 2014]
AstraZeneca Heart Drug Trial No Longer Subject ... [Published TheStreet.com - Aug 20 2014]
Brilinta bill of health boosts AstraZeneca [Published PMLive - Aug 20 2014]
AstraZeneca says Justice probe is over [Published Philly.com - Aug 19 2014]
U.S.ends probe of AstroZeneca's allegedly rigge... [Published CBS News - Aug 19 2014]
Why This Top Bio med Player Chose Cambridge [Published Noodls - Aug 19 2014]
AstraZeneca Allowed to Market Heart Drug as Fed... [Published TheStreet.com - Aug 19 2014]
US Department of Justice closes investigation i... [Published PharmiWeb - Aug 19 2014]
AstraZeneca : FTSE hits three week high with As... [Published 4 Traders - Aug 19 2014]
DoJ clears AstraZeneca for a U.S. Brilinta takeoff [Published FiercePharma - Aug 19 2014]
AZ gets all-clear in the USA over Brilinta data [Published Pharma Times - Aug 19 2014]
US DoJ closes investigation into AstraZeneca’s ... [Published Pharma Letter - Aug 19 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pfizer Back For AstraZeneca? Year-end Move Seen... [Published Clusterstock - Aug 21 2014]
By Ben Hirschler LONDON (Reuters) - Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds) takeover attempt ...
US Department of Justice Closes Investigation i... [Published Business Wire Health News - Aug 19 2014]
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA® (ticagrelor) tablets. The government ...
AstraZeneca bolsters defences with strong sales [Published Proactiveinvestors United Kingdom website - Jul 31 2014]
AstraZeneca ( LON:AZN ) primed its defences against another assault from US pharma Pfizer by blasting past forecasts helped by a surge in sales of heart drug Brilinta. Sales rose by 4% to US$6.45bn (£3.8bn) in the three months to June  as  heart drug ...
"Not My Pay" says AZ's Soriot [Published The Big Red Biotech Blog - Jun 02 2014]
Fierce Pharma characterizes AZ's CEO Pascal Soriot as bristling to the idea that executive pay (including his own) should be tied to the sales forecast that he and board chairman Leif Johansson tossed out there as they tried to fend off Pfizer's takeover ...
Pfizer Decides AstraZeneca Isn’t Worth the Trou... [Published Wall St. Cheat Sheet - May 27 2014]
Source: Thinkstock After months of the chase, it seems Pfizer Inc.  ( NYSE:PFE ) has finally given up on its pursuit of British-Swedish drugmaker AstraZeneca Group Plc  ( NYSE:AZN ). The company announced in a statement on Monday that it would ...
1 2 3 4

Press Releases

sort by: Date | Relevance
US DOJ Closes Investigation into Plato [Published GlobeNewswire: Acquisitions News - Aug 19 2014]
AstraZeneca agrees strategic transaction with A... [Published AstraZeneca - Jul 30 2014]
Director/PDMR Shareholding [Published GlobeNewswire: Acquisitions News - Jul 01 2014]
ASTRAZENECA UPDATES ON THE RAPID PROGRESS OF ON... [Published GlobeNewswire: Advertising News - Jun 03 2014]
ASTRAZENECA BOARD REJECTS PFIZER’S FINAL PROPOSAL [Published AstraZeneca - May 19 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.